Navigation Links
Zetia Does Not Reduce Carotid Plaque Size When Added to Zocor
Date:1/15/2008

BEVERLY HILLS, Calif., Jan. 15 /PRNewswire/ -- Zetia (ezetimibe) "may not actually prevent heart attacks and strokes," according to the long-awaited results of the Enhance trial. Typically, patients "take Zetia in the form of Vytorin (ezetimibe and simvastatin), which combines Zetia with Zocor (simvastatin)." Zetia and Vytorin are jointly marketed by Merck & Co. and Schering-Plough Corp.

Zetia reduces cholesterol 15 to 20 percent in most patients, no trial has been completed yet that has ever shown that it can reduce heart attacks and strokes -- or even that it reduces the growth of the fatty plaques in arteries that can cause heart problems. The Enhance trial "was designed to show that Zetia could reduce the growth" of fatty plaques in arteries. However, "the plaques actually grew by 0.005 mm more in those taking Zetia along with Zocor than in those taking Zocor alone."

The trial was conducted by a group headed by Dr. John J.P. Kastelein of the University of Amsterdam Medical Center. All 720 participants suffered from an unusual condition known as heterozygous familial hypercholesterolemia. Vytorin cut "LDL levels by 58 percent, compared to a 41 percent reduction with simvastatin alone. However, the researchers found that "the average thickness of the carotid artery plaque increased by 0.0111 of a millimeter in patients taking Vytorin, compared to an increase of 0.0058 of a millimeter in" those taking only simvastatin. According to Dr. Norman Lepor, Westside Medical Associates of Los Angeles and an expert on the treatment of hyperlipidemia, "The complete clinical trial results will be researchers plan to present their data in March at a meeting of the American College of Cardiology." He also said that "one should not confuse the very, very small increase in carotid plaque dimension with a risk of cardiovascular events, as this event data has not yet been presented. Since there do not seem to be any safety issues, there is no urgency to having patients taken off Zetia and replaced with either higher doses of statins, niacin or resins until the full clinical trial results are presented."

Westside Medical Associates of Los Angeles (WMALA) and Westside Medical Imaging (WMI) are premier centers in cardiac diagnosis and treatment.


'/>"/>
SOURCE Westside Medical Associates of Los Angeles
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
2. Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH)
3. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
4. Minimally Invasive Treatment Reduces Shoulder Pain From Tendonitis
5. Health Experts and Families Encourage Annual Childhood Flu Vaccination to Reduce Flu-Related Illnesses and Deaths in Children
6. LAP-BAND(R) System Weight-Loss Surgery Associated With More Than 70 Percent Reduced Risk of Death in People With Severe Obesity
7. Smokefree Workplace Law Reduces Heart Attacks 59% Among Nonsmokers, New Research Shows
8. Cogentus to Launch Phase III Program of Novel Combination Product Designed to Reduce Bleeding Side Effect of Antiplatelet Therapy
9. New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
10. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
11. CV Therapeutics Anti-Ischemic Agent Ranexa(R) Significantly Reduces HbA1c and Other Markers of Diabetes in MERLIN TIMI-36
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... -- Ahead of today,s trading session, Stock-Callers.com draws investors, ... at the close: Kite Pharma Inc. (NASDAQ: KITE ), ... and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN ). According to ... Friday, January 20 th , 2017, down on the day by ... stocks now at: ...
(Date:1/23/2017)... 2017 Longer life expectancy and rising healthcare expenditure ... for medical device technologies. BCC Research reveals in its new ... region, should see strong growth due to rising government healthcare ... Continue Reading ... ...
(Date:1/23/2017)... -- ResMed (NYSE: RMD ), BMC (Peking, ... Winter Haven, Florida ) gaben heute bekannt, dass ... globalen Rechtsstreitigkeiten zwischen den Parteien geeinigt haben. BMC und ... im Tausch gegen Lizenzgebühren an ResMed gestattet, und ResMed ... in Florida anhängige Rechtsverfahren zwischen ...
Breaking Medicine Technology:
(Date:1/23/2017)... Pass, OR (PRWEB) , ... January 23, 2017 , ... ... took to the air to educate listeners about the benefits of making new water ... the U.S.,” Kleyne said, “it’s appropriate that we expect water infrastructure to become a ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... earned organic certification under the USDA National Organic Program (NOP) for its Portland ... we have established organic production and handling systems to complement our current rigorous ...
(Date:1/23/2017)... ... ... at the Mill”: a story of love and redemption, hope and uncertainty as a ... , “The Inn at the Mill” is the creation of published author, Lois Kulp, ... now living in Berks County on Crow Hill. The inn, the mill and ...
(Date:1/23/2017)... ... , ... Valentine’s Day is a time when many people celebrate romance and love by giving ... looking for the ideal present, Atlanta-based Perimeter Plastic Surgery is offering a Valentine’s ... spend $200 and get $50 free. , “A lot of people just buy the ...
(Date:1/21/2017)... ... January 21, 2017 , ... Caronlab Australia, an Australian company ... ECRM Trade Show in Hilton Head, SC, where it benefited from outstanding meetings with ... of its beauty and wellness products. At this trade show, the company had the ...
Breaking Medicine News(10 mins):